갈색세포종 및 부신경절종(PCPG) - 시장 인사이트, 역학, 시장 예측(2036년)

Pheochromocytoma and Paraganglioma (PCPG) Insights and Trends

• According to DelveInsight's analysis, PCPG market size was found to be ~USD 300 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Approximately 10% of pheochromocytomas and 40% of paragangliomas are classified as malignant. Germline genetic mutations have been identified in roughly 30% of patients. Certain mutations, especially those affecting the SDHx genes, are associated with a higher probability of malignant transformation.
• The age-related rise in PCPG burden reflects the greater likelihood of tumor detection in middle-aged and older adults, driven by the cumulative impact of genetic susceptibility, prolonged exposure to physiological stressors, and the increasing use of advanced diagnostic imaging. In addition, routine abdominal imaging and endocrine evaluations in older populations frequently identify adrenal incidentalomas, contributing to a higher concentration of diagnosed cases in later decades of life compared with younger age groups.
• Almost 75% of the PCPG cases are benign with surgery as the standard of care (SOC), whereas the remaining 25% are metastatic cases with surgery, radiation, chemotherapy, radioligand therapies along with targeted therapies (sunitinib, lenvatinib, pazopanib, everolimus, and sorafenib) as SOC.
• The introduction of WELIREG into the PCPG treatment landscape in 2025, represents a significant advance in a field with limited systemic options. By targeting the hypoxia-inducible factor (HIF) pathway, a key driver in many PCPG tumors, it introduces a mechanism-based therapeutic approach aligned with tumor biology. Its availability expands targeted treatment options, supports the shift toward precision oncology, and may stimulate further innovation and biomarker-driven strategies in the PCPG therapeutic space.
• Pharmaceutical companies developing therapies to treat PCPG include: Perspective Therapeutics (VMT-a-NET), Novartis (LUTATHERA/Lutetium [177Lu]), Jazz Pharmaceuticals (ONC206/JZP3507), and Nxera Pharma (HTL0039732).
• Limited sensitivity of current biomarkers and histopathology to detect small lesions or predict metastatic potential in PCPG necessitates prolonged monitoring and highlights the need for reliable predictive biomarkers to improve risk stratification and guide treatment decisions.

Pheochromocytoma and Paraganglioma (PCPG) Market Size and Forecast in the 7MM

• 2025 PCPG Market Size: ~USD 300 million
• 2036 Projected PCPG Market Size: ~USD 670 million
• PCPG Growth Rate (2026-2036): 7.3% CAGR

DelveInsight's 'Pheochromocytoma and Paraganglioma (PCPG) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the PCPG, historical and forecasted epidemiology, as well as the PCPG market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Pheochromocytoma and Paraganglioma (PCPG) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, PCPG patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in PCPG and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Pheochromocytoma and Paraganglioma (PCPG) Market

Rising PCPG Incidence

The increasing incidence of PCPG, particularly among older adults, is primarily driven by increased use of genetic screening and greater clinical awareness leading to earlier diagnosis of previously unrecognized cases. In the US, in 2025, there were ~2,400 incident cases of PCPG, which will further increase by 2036.

Rising Opportunities in Radioligand Therapies

Emerging evidence supporting the superior efficacy and safety of Lutetium (177Lu) oxodotreotide (Lutathera), particularly following the discontinuation of the approved radioligand Iobenguane I-131 (Azedra), underscores a growing opportunity for drug developers to advance innovation in radioligand therapies.

Emerging PCPG Competitive Landscape

Some of the PCPG drugs in clinical trials include VMT-a-NET (Perspective Therapeutics), Lutetium (177Lu) oxodotreotide/LUTATHERA (Novartis), ONC206/JZP3507 (Jazz Pharmaceuticals), HTL0039732 (Nxera Pharma), and others.

Pheochromocytoma and Paraganglioma (PCPG) Understanding and Treatment Algorithm

Pheochromocytoma and Paraganglioma (PCPG) Overview and Diagnosis

PCPGs are rare neuroendocrine tumors (NETs) arising from neural crest-derived chromaffin cells. Pheochromocytomas originate in the adrenal medulla and typically secrete catecholamines, causing characteristic clinical symptoms. While paragangliomas arise from extra-adrenal paraganglia located along the sympathetic and parasympathetic nervous systems throughout the body.

Diagnosis of PCPG primarily involves biochemical testing followed by imaging confirmation. The initial step is measuring plasma free metanephrines or 24-hour urinary fractionated metanephrines, which are highly sensitive markers of catecholamine excess produced by these tumors. If biochemical results are elevated, imaging studies such as CT or MRI are performed to localize the tumor, while functional imaging (e.g., MIBG scintigraphy or PET scans) may be used to detect metastatic or extra-adrenal disease. Genetic testing is also recommended for many patients, as a significant proportion of PCPG cases are associated with hereditary syndromes.

Current Pheochromocytoma and Paraganglioma (PCPG) Treatment Landscape

The treatment of PCPG is primarily centered on surgical resection, which remains the only curative option for localized disease. Prior to surgery, patients undergo preoperative medical management with a-adrenergic blockers, followed by B-blockers if required, to control catecholamine-induced hypertension and prevent perioperative complications. For unresectable, recurrent, or metastatic disease, treatment options include radiopharmaceutical therapies such as 131I-MIBG and peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE, along with systemic therapies like chemotherapy (cyclophosphamide, vincristine, dacarbazine or temozolomide-based regimens) and targeted therapies such as the HIF-2a inhibitor belzutifan.

Pheochromocytoma and Paraganglioma (PCPG) Unmet Needs

The section "unmet needs of Pheochromocytoma and Paraganglioma (PCPG)" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of effective therapies for advanced disease

2. Surveillance and long-term monitoring

3. Lack of reimbursement programs

4. Early detection and diagnosis, and others.....

Pheochromocytoma and Paraganglioma (PCPG) Epidemiology

Key Findings from PCPG Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, the total number of incident cases of PCPG in the 7MM were ~4,900.
• In the US, germline or somatic mutations accounted for ~1,800 cases in 2025, while the ~600 cases were associated with tumors with no genetic alterations.
• In Japan, the highest number of age-specific incident PCPG cases in 2025 was observed in the 50-74 years age group (~340 cases), while individuals aged under 25 years accounted for the lowest number of cases (~46).
• In the US, localized PCPG accounted for the majority of diagnoses compared with metastatic disease, reflecting the tendency for most tumors to be detected before distant spread, although all PCPGs retain metastatic potential.

Pheochromocytoma and Paraganglioma (PCPG) Drug Analysis & Competitive Landscape

The PCPG drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the PCPG treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the PCPG therapeutics market.

Approved Therapies for Pheochromocytoma and Paraganglioma (PCPG)

Belzutifan (WELIREG): Merck

Belzutifan (WELIREG), developed by Merck, is a novel, potent, and selective inhibitor of HIF-2a. Initially it was approved for VHL disease-associated tumors and subsequently for RCC, its approval in May 2025 for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic PCPG represents a strategic expansion into a rare tumor indication.

Pheochromocytoma and Paraganglioma (PCPG) Pipeline Analysis

Lutetium [177Lu] oxodotreotide/dotatate (LUTATHERA): Novartis

Lutetium [177Lu] oxodotreotide is a PRRT developed and marketed by Novartis. It comprises the somatostatin analogue dotatate radiolabeled with the beta-emitting isotope lutetium-177, enabling targeted delivery of ionizing radiation to tumor cells expressing somatostatin receptors (predominantly Subtype 2). As the PCPG cohort in the NETTER-P study was exploratory and Novartis has not disclosed further development plans for this indication. Therefore, DelveInsight assumes that Novartis may need to initiate a dedicated registrational trial in PCPG. If initiated soon, considering ~2.5-3 years for trial completion and ~1 year for approval, the potential launch could occur around 2031.

Pheochromocytoma and Paraganglioma (PCPG) Key Players, Market Leaders and Emerging Companies

• Merck
• Bausch Health
• Ono Pharmaceutical
• Shionogi
• Nippon Kayaku
• Kyowa Hakko Kirin
• Novartis
• Jazz Pharmaceuticals
• Perspective Therapeutics
• Nxera Pharma, and others

Pheochromocytoma and Paraganglioma (PCPG) Drug Updates

• As of January 2026, LUTATHERA's US orphan drug exclusivity has expired, but formulation patents remain valid until 2039 (including pediatric exclusivity) and are currently under challenge by generic applicants. In the EU, its primary patent protection is expected to expire in 2029.
• In January 2026, Perspective Therapeutics presented updated interim results from its ongoing Phase I/II trial evaluating [212Pb]VMT-a-NET in patients with unresectable or metastatic SSTR2-expressing NETs as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI).
• In June 2025, Perspective Therapeutics aligned with the US FDA to open Cohort 3 in its Phase I/IIa trial of [212Pb]VMT-a-NET for patients with unresectable or metastatic SSTR2-positive NETs who have not previously received radiopharmaceutical therapy.

Pheochromocytoma and Paraganglioma (PCPG) Market Outlook

The PCPG market is undergoing a gradual transformation after decades of relying mainly on surgery, symptomatic management, and limited systemic therapies such as chemotherapy and radionuclide treatments. Recent advances in precision oncology have begun to reshape the landscape, highlighted by the FDA approval of belzutifan (WELIREG) in May 2025, the first oral targeted therapy for patients with locally advanced, unresectable, or metastatic PCPG. This milestone validates HIF-2a inhibition as a therapeutic strategy and establishes a regulatory precedent for targeted treatments in this rare neuroendocrine tumor segment.

Alongside this approval, emerging modalities such as radiopharmaceutical therapies (e.g., 131I-MIBG and PRRT with 177Lu-DOTATATE) and investigational radioligand approaches are expanding treatment options for advanced disease. Meanwhile, pipeline candidates including novel radioligands, targeted inhibitors, and combination approaches are progressing through clinical development, indicating that the PCPG treatment paradigm is gradually shifting toward mechanism-driven and precision-based therapies, similar to the evolution seen in other rare oncology markets.

Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM PCPG market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest market size of PCPG. i.e., USD ~200 million in 2025
• In 2036, among all the therapies for PCPG, the highest revenue is estimated to be generated by belzutifan (WELIREG), in the US.
• The entry of mid-stage candidates such as JZP3507 (ONC206) is expected to intensify competition in the PCPG treatment landscape during the latter half of the forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in PCPG (2022-2036 Forecast)

The PCPG market comprises radioligand therapies, and small molecules, each targeting different aspects of PCPG.

• Radioligand therapies: Lutetium-177 dotatate (LUTATHERA) and [212Pb]VMT-a-NET represent targeted radiopharmaceutical approaches for SSTR2-positive neuroendocrine tumors, where LUTATHERA delivers B-particle radiation through PRRT, while [212Pb]VMT-a-NET is an emerging alpha-emitting radioligand designed to enhance tumor-specific cytotoxicity.
• Small molecules: Approved therapies such as belzutifan (WELIREG), metyrosine (DEMSER), and pipeline candidates such as JZP3507 (ONC206) and HTL0039732, targeting hypoxia signaling, catecholamine synthesis, and tumor survival pathways.

Small molecules defines the core innovation landscape, with radioligand therapies currently commercially validated and small molecules driving pipeline growth.

Pheochromocytoma and Paraganglioma (PCPG) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the PCPG drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in PCPG is expected to vary based on clinical positioning, mechanism of action, and stage of development. Recently approved targeted therapy such as belzutifan (WELIREG) is projected to demonstrate relatively faster uptake, driven by its first-in-class HIF-2a inhibition, oral administration, and strong clinical need in advanced or unresectable disease.

In contrast, pipeline candidate JZP3507 (ONC206) is expected to follow a moderate uptake trajectory, reflecting its investigational status and gradual adoption as clinical evidence emerges. Meanwhile, LUTATHERA (Lutetium-177 dotatate) is anticipated to show gradual uptake, as its use is generally limited to SSTR-positive tumors and requires specialized radiopharmaceutical infrastructure, which may restrict broader adoption despite its established role in neuroendocrine tumors.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Pheochromocytoma and Paraganglioma (PCPG)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Pheochromocytoma and Paraganglioma (PCPG) Therapies Price Scenario & Trends

Pricing and analogue assessment of PCPG therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Pheochromocytoma and Paraganglioma (PCPG) Approved Drugs

WELIREG (belzutifan), which is already approved in other cancer indications has a list price of USD 31,162.50 per bottle of 90 tablets. The overall response for the therapy was about 21 months, we have calculated cost for 12 months resulting in an annual cost of USD 373,950.

Industry Experts and Physician Views for Pheochromocytoma and Paraganglioma (PCPG)

To keep up with PCPG market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the PCPG emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in PCPG, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Cancer Research Institute at Beth Israel Deaconess Medical Center, University of Wurzburg, and Cardiovascular Prevention Institute, etc. were contacted.Their opinion helps understand and validate current and emerging PCPG therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in PCPG.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of PCPG, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of PCPG, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the PCPG market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM PCPG market.

Report Insights

• Pheochromocytoma and Paraganglioma (PCPG) Patient Population Forecast
• Pheochromocytoma and Paraganglioma (PCPG) Therapeutics Market Size
• Pheochromocytoma and Paraganglioma (PCPG) Pipeline Analysis
• Pheochromocytoma and Paraganglioma (PCPG) Market Size and Trends
• Pheochromocytoma and Paraganglioma (PCPG) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Pheochromocytoma and Paraganglioma (PCPG) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Pheochromocytoma and Paraganglioma (PCPG) Treatment Addressable Market (TAM)
• Pheochromocytoma and Paraganglioma (PCPG) Competitive Landscape
• Pheochromocytoma and Paraganglioma (PCPG) Major Companies Insights
• Pheochromocytoma and Paraganglioma (PCPG) Price Trends and Analogue Assessment
• Pheochromocytoma and Paraganglioma (PCPG) Therapies Drug Adoption/Uptake
• Pheochromocytoma and Paraganglioma (PCPG) Therapies Peak Patient Share Analysis

Report Assessment

• Pheochromocytoma and Paraganglioma (PCPG) Current Treatment Practices
• Pheochromocytoma and Paraganglioma (PCPG) Unmet Needs
• Pheochromocytoma and Paraganglioma (PCPG) Clinical Development Analysis
• Pheochromocytoma and Paraganglioma (PCPG) Emerging Drugs Product Profiles
• Pheochromocytoma and Paraganglioma (PCPG) Market attractiveness
• Pheochromocytoma and Paraganglioma (PCPG) Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the PCPG market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of PCPG?
• What are the disease risks, burdens, and unmet needs of PCPG? What will be the growth opportunities across the 7MM concerning the patient population with PCPG?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of PCPG? What are the current guidelines for treating PCPG in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the PCPG market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Methodology of Pheochromocytoma and Paraganglioma (PCPG)

6. Pheochromocytoma and Paraganglioma (PCPG) Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of PCPG By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of PCPG By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Pheochromocytoma and Paraganglioma (PCPG)

• 7.1. Introduction
• 7.2. Types of PCPG
• 7.3. Molecular Classification of PCPG
• 7.4. Causes
• 7.5. Signs And Symptoms
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm
  • 7.6.3. Diagnostic Guidelines
    • 7.6.3.1. NCCN Guidelines for Diagnosis of PCPG (2025)
    • 7.6.3.2. International Expert Consensus Statement on Management of PCPG in Patients With Germline SDHB Pathogenic Variants (2024)
    • 7.6.3.3. North American Neuroendocrine Tumor Society (NANETS) Guidelines (2022)
    • 7.6.3.4. European Standard Clinical Practice (ESCP) (2025)
    • 7.6.3.5. Japan Endocrine Society Clinical Practice Guideline (2025)
• 7.7. Treatment and Management
• 7.8. Treatment Algorithm
• 7.9. Treatment Guidelines
  • 7.9.1. NCCN Guidelines for PCPG (2025)
  • 7.9.2. International Expert Consensus Statement on Management of PCPG in Patients with Germline SDHB Pathogenic Variants (2024)
  • 7.9.3. North American Neuroendocrine Tumor Society (NANETS) Guidelines (2022)
  • 7.9.4. American Association of Endocrine Surgeons Guidelines for Adrenalectomy (2022)
  • 7.9.5. European Standard Clinical Practice (ESCP) (2025)
  • 7.9.6. Japan Endocrine Society Clinical Practice Guideline (2025)

8. Epidemiology and Patient Population of Pheochromocytoma and Paraganglioma (PCPG)

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Incident Cases of PCPG in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of PCPG in the United States
  • 8.4.2. Occurrence or Absence of Mutation in PCPG in the United States
  • 8.4.3. Age-specific Incident Cases of PCPG in the United States
  • 8.4.4. Stage-specific Incident Cases of PCPG in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of PCPG in EU4 and the UK
  • 8.5.2. Occurrence or Absence of Mutation in PCPG in EU4 and the UK
  • 8.5.3. Age-specific Incident Cases of PCPG in EU4 and the UK
  • 8.5.4. Stage-specific Incident Cases of PCPG in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Incident Cases of PCPG in Japan
  • 8.6.2. Occurrence or Absence of Mutation in PCPG in Japan
  • 8.6.3. Age-specific Incident Cases of PCPG in Japan
  • 8.6.4. Stage-specific Incident Cases of PCPG in Japan

9. Patient Journey of Pheochromocytoma and Paraganglioma (PCPG)

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Pheochromocytoma and Paraganglioma (PCPG)
• 10.2. Metyrosine (DEMSER): Bausch Health And Ono Pharmaceutical
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst Views
• 10.3. Belzutifan (WELIREG): Merck
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Summary of Pivotal Trials
  • 10.3.4. Analyst Views

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of Pheochromocytoma and Paraganglioma (PCPG)
• 11.2. Lutetium [177lu] oxodotreotide/dotatate (Lutathera): Novartis
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trial Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst Views
• 11.3. JZP3507 (ONC206): Jazz Pharmaceuticals
  • 11.3.1. Product Description
  • 11.3.2. Clinical Development
    • 1.1.1.1. Clinical Trial Information
  • 11.3.3. Analyst Views
• 11.4. [212Pb] VMT-a-Net: Perspective Therapeutics
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Development
    • 11.4.3.1. Clinical Trial Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Analyst Views

12. Pheochromocytoma and Paraganglioma (PCPG): Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Pheochromocytoma and Paraganglioma (PCPG)
• 12.3. Conjoint Analysis of Pheochromocytoma and Paraganglioma (PCPG)
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of PCPG in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of PCPG in the United States
  • 12.6.2. Market Size of PCPG by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of PCPG in EU4 and the UK
  • 12.7.2. Market Size of PCPG by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of PCPG in Japan
  • 12.8.2. Market Size of PCPG by Therapies in Japan

13. Unmet Needs of Pheochromocytoma and Paraganglioma (PCPG)

14. SWOT Analysis of Pheochromocytoma and Paraganglioma (PCPG)

15. KOL Views of Pheochromocytoma and Paraganglioma (PCPG)

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Pheochromocytoma and Paraganglioma (PCPG)

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of PCPG Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight